Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGas, bloating and wind are among the most commonly reported side effects of Wegovy (semaglutide), particularly in the first few weeks of treatment. They occur because semaglutide slows gastric emptying, giving food longer to ferment in the gut, which produces more gas than usual. For most people these effects are mild and settle as the body adjusts, but they can be uncomfortable enough to affect daily life. Wegovy is a prescription-only medicine, which means a GPhC-registered prescriber assesses your suitability before any treatment begins, and that clinical conversation is exactly the right place to raise concerns about side effects before they start.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide activates GLP-1 receptors in the gut as well as the brain. One of its key actions is slowing how quickly the stomach empties into the small intestine. That slower transit means food sits in the digestive tract longer than it normally would, giving gut bacteria more time to ferment carbohydrates and fibre. The byproduct of that fermentation is gas. The result can be bloating, a feeling of fullness that lingers well past a meal, and more flatulence or burping than you are used to.
This is not a sign that something has gone wrong. It is a predictable consequence of how the medicine works. The NHS semaglutide patient information page lists flatulence, belching and bloating among the known side effects, and they appear in the medicine's clinical trial data too. Understanding that the mechanism is pharmacological rather than coincidental can make these symptoms feel a lot more manageable.
If you want a fuller picture of how Wegovy's side effects present across the board, the Wegovy side effects overview covers the complete profile. For the specific pairing of gas with loose stools, our page on Wegovy gas and diarrhoea goes into more detail on that combination.
Yes, but the severity varies considerably. In semaglutide's STEP clinical trials, gastrointestinal side effects as a group were reported by a significant proportion of participants, with flatulence and abdominal distension appearing in the side-effect tables at frequencies classified as common or very common. Some people barely notice any change; others find the first month at a new dose genuinely disruptive.
The pattern most people describe is a peak in the first one to three weeks after starting or after a dose increase, followed by a gradual improvement as the gut adapts. For most, the gas is mild and intermittent rather than constant. A smaller group finds it persistent enough to ask their prescriber about slowing the dose escalation, which is a legitimate clinical option.
There is also a question our prescribers hear fairly often: could someone be on the right dose for them and genuinely have very few GI symptoms? The answer is yes. Our page on experiencing no side effects on Wegovy explains why that happens and what it means for treatment.
For a broader look at the medicine itself before going further, the Wegovy treatment guide covers the full context, including how semaglutide works and who it is licensed for in the UK.
Several straightforward adjustments make a measurable difference for most people. Eating more slowly matters more than most people expect: swallowing less air while chewing reduces the amount of gas entering the digestive tract directly. Smaller, more frequent meals reduce the volume sitting in a slowing stomach at any one time.
Foods that ferment quickly (cruciferous vegetables like broccoli and cabbage in large quantities, onions, fizzy drinks, high-fat fried foods) tend to amplify Wegovy's already-slowing effect on digestion. That does not mean cutting them out permanently, but reducing them during the adjustment phase can ease discomfort significantly. Staying well hydrated helps gut motility keep moving.
Over-the-counter remedies for wind are generally safe alongside semaglutide, but checking with a pharmacist or your prescriber before adding anything new is always sensible. The Wegovy gas and burping page has specific practical tips for managing the burping side of this, which often responds to slightly different techniques than flatulence. More detail on the full digestive picture is also on whether gas is a confirmed Wegovy side effect.
Ordinary flatulence, bloating and burping on Wegovy do not need urgent review. But some abdominal symptoms warrant a call or visit to a doctor without delay. Severe abdominal pain that is persistent and radiates towards the back, with or without vomiting, can be a sign of acute pancreatitis. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known but infrequent GLP-1 side effect that can be serious. That symptom pattern is different from the dull bloating most people experience: it is intense, does not settle on its own, and may worsen after eating.
Other symptoms worth raising with a prescriber sooner rather than later include: pain in the upper right abdomen that could suggest gallbladder involvement, signs of dehydration following severe vomiting or diarrhoea, or any symptom that is getting worse rather than better after the first few weeks at a stable dose.
Suspected side effects, including those you are not sure are related to the medicine, can be reported directly to the MHRA at the Yellow Card scheme. Patients as well as clinicians can submit reports, and doing so helps regulators build a fuller picture of how these medicines behave in real-world use. If you have a question between reviews, our aftercare team is available seven days a week.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.